New Analyses Suggest Favorable Results for STELARA® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, Pa., Oct. 25, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Corporations of Johnson & Johnson at the moment introduced ...
